One controllable payload. Multiple partner programmes.
GenLumina is developing a light-activated intracellular payload that can be combined with different antibodies, peptides or ligands. Our internal programmes generate evidence for the platform. Pharmaceutical partners can then evaluate the same payload with targeting biology relevant to their own pipelines.
Selectivity is built in twice.
Starting points that demonstrate platform breadth.
GL-001 and GL-002 are internal evidence programmes used to validate different targeting modalities, tumor settings and development questions. They demonstrate what the platform can do; they do not limit GenLumina to these targets or indications.
Internal programmes generate transferable knowledge around conjugation, uptake, intracellular localization, controlled activation, safety and efficacy. New programmes can be created around targeting biology selected by pharmaceutical partners.
EpCAM
Colorectal cancer · MSS/pMMR
Demonstrates peptide-targeted platform application
Proprietary peptide
HER2
HER2-expressing solid tumors
Demonstrates antibody-targeted platform application
Anti-HER2 mAb
Your targeting biology can become the next programme.
A pharma or biotech partner does not need to adopt GL-001 or GL-002. It can bring an antibody, peptide or ligand from its own pipeline and evaluate the GenLumina payload in a separately defined proof-of-concept programme.
A pipeline designed to expand through partners.
One controllable payload
The same light-activated intracellular payload can be evaluated across multiple targeting approaches and indications.
Partner-owned biology
Antibodies, peptides or ligands can be selected around each partner's existing pipeline, target biology and indication priorities.
Programme by programme
Each combination can follow its own PoC, decision criteria, financing and indication-specific licensing route.
GenLumina retains the core
Programme-specific rights can be licensed while GenLumina preserves ownership of the underlying payload platform for additional partners and applications.
Evidence before expansion.
Internal and partner programmes progress through the same evidence logic. The objective is to answer specific technical and biological questions before larger development commitments or commercial rights are triggered.
Bring your targeting biology.
GenLumina can define a focused PoC around an antibody, peptide or ligand relevant to your pipeline. We can agree upfront which scientific criteria should determine whether a successful programme progresses toward an indication- and territory-specific licensing option.